A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer
© 2024. The Author(s)..
There are few effective treatments for small cell lung cancer (SCLC) underscoring the need for innovative therapeutic approaches. This study focuses on exploiting telomerase, a critical SCLC dependency as a therapeutic target. A prominent characteristic of SCLC is their reliance on telomerase activity, a key enzyme essential for their continuous proliferation. Here we utilize a nucleoside analog, 6-Thio-2'-deoxyguanosine (6TdG) currently in phase II clinical trials, that is preferentially incorporated by telomerase into telomeres leading to telomere dysfunction. Using preclinical mouse and human derived models we find low intermittent doses of 6TdG inhibit tumor growth and reduce metastatic burden. Anti-tumor efficacy correlates with a reduction in a subpopulation of cancer initiating like cells (CICs) identified by their expression of L1CAM/CD133 and highest telomerase activity. 6TdG treatment also leads to activation of innate and adaptive anti-tumor responses. Mechanistically, 6TdG depletes CICs and induces type-I interferon signaling leading to tumor immune visibility by activating tumor cell STING signaling. We also observe increased sensitivity to irradiation after 6TdG treatment in both syngeneic and humanized SCLC xenograft models both of which are dependent on the presence of host immune cells. This study underscores the immune-enhancing and metastasis-reducing effects of 6TdG, employing a range of complementary in vitro and in vivo SCLC preclinical models providing a potential therapeutic approach to SCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nature communications - 15(2024), 1 vom: 22. Jan., Seite 672 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eglenen-Polat, Buse [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2133-81-5 |
|---|
| Anmerkungen: |
Date Completed 24.01.2024 Date Revised 10.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-024-44861-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367440407 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367440407 | ||
| 003 | DE-627 | ||
| 005 | 20240210233147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240123s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-024-44861-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM367440407 | ||
| 035 | |a (NLM)38253555 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eglenen-Polat, Buse |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2024 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a There are few effective treatments for small cell lung cancer (SCLC) underscoring the need for innovative therapeutic approaches. This study focuses on exploiting telomerase, a critical SCLC dependency as a therapeutic target. A prominent characteristic of SCLC is their reliance on telomerase activity, a key enzyme essential for their continuous proliferation. Here we utilize a nucleoside analog, 6-Thio-2'-deoxyguanosine (6TdG) currently in phase II clinical trials, that is preferentially incorporated by telomerase into telomeres leading to telomere dysfunction. Using preclinical mouse and human derived models we find low intermittent doses of 6TdG inhibit tumor growth and reduce metastatic burden. Anti-tumor efficacy correlates with a reduction in a subpopulation of cancer initiating like cells (CICs) identified by their expression of L1CAM/CD133 and highest telomerase activity. 6TdG treatment also leads to activation of innate and adaptive anti-tumor responses. Mechanistically, 6TdG depletes CICs and induces type-I interferon signaling leading to tumor immune visibility by activating tumor cell STING signaling. We also observe increased sensitivity to irradiation after 6TdG treatment in both syngeneic and humanized SCLC xenograft models both of which are dependent on the presence of host immune cells. This study underscores the immune-enhancing and metastasis-reducing effects of 6TdG, employing a range of complementary in vitro and in vivo SCLC preclinical models providing a potential therapeutic approach to SCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Telomerase |2 NLM | |
| 650 | 7 | |a EC 2.7.7.49 |2 NLM | |
| 650 | 7 | |a alpha-2'-deoxythioguanosine |2 NLM | |
| 650 | 7 | |a 2133-81-5 |2 NLM | |
| 650 | 7 | |a Deoxyguanosine |2 NLM | |
| 650 | 7 | |a G9481N71RO |2 NLM | |
| 650 | 7 | |a Thionucleosides |2 NLM | |
| 700 | 1 | |a Kowash, Ryan R |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Hai-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Siteni, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Mingrui |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Kenian |e verfasserin |4 aut | |
| 700 | 1 | |a Bender, Matthew E |e verfasserin |4 aut | |
| 700 | 1 | |a Mender, Ilgen |e verfasserin |4 aut | |
| 700 | 1 | |a Stastny, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Drapkin, Benjamin J |e verfasserin |4 aut | |
| 700 | 1 | |a Raj, Prithvi |e verfasserin |4 aut | |
| 700 | 1 | |a Minna, John D |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Shay, Jerry W |e verfasserin |4 aut | |
| 700 | 1 | |a Akbay, Esra A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 15(2024), 1 vom: 22. Jan., Seite 672 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:22 |g month:01 |g pages:672 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-024-44861-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 22 |c 01 |h 672 | ||